Silo Pharma, Inc. SILO
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -25.00% | 0.00% | 0.00% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -25.00% | 0.00% | 0.00% | -- | -- |
| Cost of Revenue | 935.00% | 960.00% | 640.00% | -- | -- |
| Gross Profit | -112.20% | -87.20% | -58.13% | -- | -- |
| SG&A Expenses | -1.53% | -8.18% | -12.96% | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.79% | -2.78% | -8.90% | -- | -- |
| Operating Income | 13.64% | 2.83% | 9.03% | -- | -- |
| Income Before Tax | 8.65% | -4.77% | 3.76% | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 8.65% | -4.77% | 3.76% | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.65% | -4.77% | 3.76% | -- | -- |
| EBIT | 13.64% | 2.83% | 9.03% | -- | -- |
| EBITDA | 13.70% | -21.98% | -51.43% | -- | -- |
| EPS Basic | 65.25% | 56.29% | 48.86% | -- | -- |
| Normalized Basic EPS | 64.73% | 56.32% | 48.79% | -- | -- |
| EPS Diluted | 65.25% | 56.29% | 48.86% | -- | -- |
| Normalized Diluted EPS | 64.73% | 56.32% | 48.79% | -- | -- |
| Average Basic Shares Outstanding | 170.47% | 161.46% | 127.53% | -- | -- |
| Average Diluted Shares Outstanding | 170.47% | 161.46% | 127.53% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |